help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, M.
Right arrow Articles by Vale, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, M.
Right arrow Articles by Vale, W.

Endocrinology, Vol 104, 1709-1715, Copyright © 1979 by Endocrine Society


ARTICLES

Somatostatin: central nervous system actions on glucoregulation

M Brown, J Rivier and W Vale

Somatostatin (SRIF) has been tested for its actions on the central nervous system to affect glucoregulation. In doses ineffective when given systemically , SRIF and SRIF analogs given intracisternally (ic) reduce hyperglycemia and hyperglucagonemia after ic bombesin administration. The SRIF analog, des-AA1, 2, 4, 5, 12, 13-[D-Trp8]SRIF, decreases plasma insulin and elevates plasma glucose and glucagon when given systemically. However, when given ic, this peptide prevents the rise in glucose and glucagon after ic bombesin administration and is 10 times more potent than SRIF in reducing bombesin-induced hyperglycemia. Other analogs of SRIF and various unrelated peptides were found to be ineffective in reducing bombesin-induced hyperglycemia. des-AA1, 2, 4, 5, 12, 13-[D-Trp]SRIF prevented the hyperglycemia induced by surgical stress or by ic administration of beta-endorphin or carbacol. des-AA1, 2, 4, 5, 12, 13-[D-Trp]SRIF given ic did not prevent hyperglycemia induced by systemic administration of epinephrine, arginine, or glucagon. These studies suggest that SRIF and its analogs may act within the brain to affect glucoregulation.


This article has been cited by other articles:


Home page
GutHome page
M Yoneda, K Nakamura, Y Nakade, M Tamano, T Kono, H Watanobe, T Shimada, H Hiraishi, and A Terano
Effect of central corticotropin releasing factor on hepatic circulation in rats: the role of the CRF2 receptor in the brain
Gut, February 1, 2005; 54(2): 282 - 288.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
M. C. Lekas, S. J. Fisher, B. El-Bahrani, M. van Delangeryt, M. Vranic, and Z. Q. Shi
Glucose uptake during centrally induced stress is insulin independent and enhanced by adrenergic blockade
J Appl Physiol, August 1, 1999; 87(2): 722 - 731.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. Yokohama, M. Yoneda, K. Nakamura, and I. Makino
Effect of central corticotropin-releasing factor on carbon tetrachloride-induced acute liver injury in rats
Am J Physiol Gastrointest Liver Physiol, March 1, 1999; 276(3): G622 - G628.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. Nouel, G. Gaudriault, M. Houle, T. Reisine, J.-P. Vincent, J. Mazella, and A. Beaudet
Differential Internalization of Somatostatin in COS-7 Cells Transfected with SST1 and SST2 Receptor Subtypes: A Confocal Microscopic Study Using Novel Fluorescent Somatostatin Derivatives
Endocrinology, January 1, 1997; 138(1): 296 - 306.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
Y Tache, Y Goto, M. Gunion, W Vale, J River, and M Brown
Inhibition of gastric acid secretion in rats by intracerebral injection of corticotropin-releasing factor
Science, November 25, 1983; 222(4626): 935 - 937.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1979 by The Endocrine Society